

### **EPA's ToxCast Program:** From Research to Application

David Dix National Center for Computational Toxicology

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

OECD Molecular Screening 26 Oct 2009 Paris, France

Office of Research and Development National Center for Computational Toxicology

26 Oct 2009

COMPUTATIO

This work was reviewed by EPA and approved for publication but does not necessarily reflect official Agency policy.



## **ToxCast<sup>™</sup> Background**


- Research program of EPA's National Center for Computational Toxicology
- Addresses chemical screening and prioritization needs for pesticidal inerts, antimicrobials, CCLs, HPVs and MPVs
- Comprehensive use of HTS technologies
- Coordinated with NTP and NHGRI/NCGC via Tox21



- Committed to stakeholder involvement and public release of data
  - Chemical Prioritization Community of Practice
  - NCCT website- http://www.epa.gov/ncct/




### **HTS in Drug Development**






### **HTS in Toxicology**






# **EPA's Need for Prioritization**



National Center for Computational Toxicology

### Too Little Data (%)





## Chemical Prioritization Pesticides: Current Status

- Antimicrobials (300 Total)
  - ~100 have undergone (re-)registration since 1996 (FQPA)
  - Limited to no toxicity information
  - Limited regulatory capacity for requesting toxicity data
  - Current practice:
    - Food-use to non-food-use chemicals
    - Chemical groupings by structure similarity
  - Potential need:
    - Biologically-based support for toxicity data requests
    - Re-registration prioritization
    - Biologically driven chemical groupings

- Inerts ('Other' Ingredients (>4500 Total))
  - Legislative mandate to (re)assess all 'other' ingredients
  - ~700 Currently re-assessed (~2500 previously assessed)
  - Limited to no toxicity information
  - Limited to no regulatory capacity for requesting toxicity data
  - Current practice:
    - •Limited use of QSAR models
    - •Use limited available information in categorical assessment
    - Tackle recognizably safe chemicals 1<sup>st</sup> (GRAS, etc.)
  - Potential need:
    - •Prioritization & Classification of Ingredients
    - •Biologically driven chemical groupings
    - Targeted testing of chemicals/groups



## Chemical Prioritization Industrial: Current Status

- HPV (~3500 Total)
  - >1Million lbs production/importation
  - 2200 Part of HPV Challenge
  - Wide range of toxicological data availability
  - Limited to no regulatory capacity for requesting toxicity data
  - Current practice:
    - HPV Categories (Chemical groupings by structural similarity)
    - Use of QSAR models
  - Potential need:
    - Biologically driven chemical groupings
    - Rapid evaluation of chemicals with no toxicity information


- MPV (~2800)
  - >25,000 lbs production/importation
  - Wide range of toxicological data availability (primarily SIDS)
  - ChAMP expanded to MPVs
  - Current practice:
    - Hazard-based (screening-level documents)
    - Consider QSAR estimates
    - Consider Canada's categorization results
  - Potential need:
    - Enhance use of models with screening data
    - Rapid evaluation of chemicals with no toxicity information



## **ToxCast\_320** 309 Unique Chemicals

- 3 Triplicates
- 5 Duplicates
- 276 Conventional Actives
- 16 Antimicrobials
- 9 Industrial Chemicals
- 8 Metabolites
- 75 Chemical Classes







## **ToxCast Assays**

### **Biochemical Assays**

- Protein families
  - GPCR
  - NR
  - Kinase
  - Phosphatase
  - Protease
  - Other enzyme
  - Ion channel
  - Transporter
- Assay formats
  - Radioligand binding
  - Enzyme activity
  - Co-activator recruitment

### 467 Total Endpoints

Office of Research and Development National Center for Computational Toxicology


### **Cellular Assays**

- Cell lines
  - HepG2 human hepatoblastoma
  - A549 human lung carcinoma
  - HEK 293 human embryonic kidney
- Primary cells
  - Human endothelial cells
  - Human monocytes
  - Human keratinocytes
  - Human fibroblasts
  - Human proximal tubule kidney cells
  - Human small airway epithelial cells
- Biotransformation competent cells
  - Primary rat hepatocytes
  - Primary human hepatocytes
- Assay formats
  - Cytotoxicity
  - Reporter gene
  - Gene expression
  - Biomarker production
  - High-content imaging for cellular <sup>8</sup> phenotype

#### **ToxCast: Pathway Coverage** States **Environmental Protection** Agency PDG nsulin PPARo Ligand PPARa Ligand IL-1B PDGFR Extracellular TNE Insulin receptor SHC GRB2 SOS Ras SOS GRB2 SHC TRAE6 TRAF2 Cytoplasm **Biologically Multiplexed** TAB1-> PPARo Ligand PPARa Ligand **Activity Profiling (BioMAP)** AK1 c-Rat NIk PPAR $\bigcirc$ **Multiplex** Transcription SP90XAP MEK1)2 **Reporter Assay** SP90 XAP2 HSP90 lκB NF-KB/ $\bigcirc$ PPARo Ligand IKB **Cell-based HTS Assays** PPARa Ligand Nucleus **Cell-free HTS Assays** PPAR PPAR **High Content Cell Imaging** $\circ$ Assays NR0B2 NCOR NCOR NCO, NCOA COR RXR RXR PPAR c-Jun c-Fos -LXR-C STAT5-STAT5 RXR RXR PIE PPRE PRF COX2 1.Fatty acid oxidation 1.Peroxisome proliferation 2.Lipid homeostatis 2.Fatty acid oxidation and degradation 3.Skin proliferation 3.Lipid homeostatis Fatty acid synthesis 4.Colon carinogenesis 4.Hepatocarcinogenesis 1.Adipocyte differentiation 2 Glucose and Insulin Homeostatis 3.Macrophage function

Office of Research and Development National Center for Computational Toxicology

#### **PPAR Signaling Pathway**





## Some Expected Results...


- Estrogen receptor (ER)
  - -Bisphenol A, Methoxychlor, HPTE
- Androgen Receptor (AR)
  - -Vinclozolin, Linuron, Prochloraz
- PPAR
  - -PFOA, PFOS, Diethylhexyl Phthalate, Lactofen
- Mitochondrial Poisons
  - -Azoxystrobin, Fluoxastrobin, Pyraclostrobin
- Acetylcholinesterase Inhibition
  - -Multiple organophosphorus pesticides



### What is a hit?

ERE\_CIS

ERa\_TRANS






### ToxCast Phase I Assay Hits (n=624 measurements)

Novascreen (Knudsen et al, NCB, submitted) Attagene (Martin et al, CRT, submitted) Bioseek (Houck et al, JBS, published) Cellumen (Houck et al, In prep) CellzDirect (Rotroff et al, TAP, submitted) Solidus (Ryan et al, In prep) ACEA (Judson et al, In prep) Gentronix (Knight et al, RTP, published)

828 Assay-Chemical Pairs had AC50s of less than 1µM





## **ToxRefDB**

- Relational phenotypic/toxicity database
  - Stores Guideline In Vivo Laboratory Animal Toxicology Data
  - All Treatment-Related Effects at All Dose Levels Captured
- Provides in vivo anchor for ToxCast predictions
- Focus: 3 study types
  - Chronic/Cancer Rat and Mouse (Martin, et al, EHP 2008)
  - Rat Multigeneration Reproductive Toxicity (Martin, et al, ToxSci 2009)
  - Rat & Rabbit Developmental Toxicity (Knudsen, et al, ReproTox 2009)
- Two types of synthesis
  - Supervised (common individual phenotypes)
  - Unsupervised (machine based clustering of phenotype patterns)



| TUDY TYPE Contained chaosic toxicity four operandly f<br>OFFTS 270-43  | 00 [663.5]  |
|--|---|
| P.C. CODE 1100   | TOX_CHEM.NO. 497AB  |
| TERT MATERIAL (PURITY) (mandationally 277 (%))<br>THORYME RO22979  |   |
| CITATION Van Dwar, K. 1999. Combined oral chan<br>D4D Berere, Belgian. Laboratory report namber, 2017, Ita   | nic toxicity/serim prairity shally with Insendil in the SPF Water ref. Dept. Tenicology, Jacons, Research Foundation,<br>no 9, 1999. MHD 4453001. Unpublished.  |
| PONDOR Jacon Phamatentics N.V., 2340 Berry   | , Belgnan   |
| DESCUTIVE SUMMARY  |   |
| Warlas-derived rate of concentrations of <b>0, 30, 300, 1300, ve</b><br>age 20/20/2007 for femaler) for two years. All rate were observe<br>Ricold and using samples were collected after 6, 12, and 13 s  | finanzia (CATURN 14) www.eduaraistendia tipe <mark>dani</mark> to groups of <b>Dimons and Dimons Resource substrates (1797)</b><br>2005 generative provide the CATURNESS and CA |
| The viscible weights of most organs were decreased while the<br>Cheek effects are considered related to immittee well import<br>for effly related to treatment. The statement of the<br>relative related to treatment.   | their weights relative to body weight increased for male and fender stat in the 1200 and 2400 ppm treatment groups,<br>increased not a dated result of locatabilitiestance. However, effects front due low and figured was considered   |
| rell and happendic fort was equipped while an analysis for   | Egensi (nube oxiy war nadrand normanjacity, taki kati datat ma ndata Balagin. The indexe of dea<br>y densemble da normanization of economical from war and head in the second of the ADI parameters of<br>generated by the normanization of economical from war and head in   |
| The learned observed adverse effect level (LOAEL) for an<br>abserve effect level (VOAEL) of 200 pp m (10.8 mg Sg ida<br>marre- and microscopic effects noted in the liver of all re  | ale and female rate was 1200 ppm (65.8 and 85.2 mg hg day, respectively) with a corresponding an observed<br>ay analos, 14.6 mg/hg/day femaler). These are based on the effects found on body weight, weight gain, and the<br>tru and the dynamic of ender wit:   |
| a difference of the dependence of the second s |   |
| This chemic toxicity/incogenicity study in the ret is Accept<br>11. No deficiencies were noted for this study  | able guideline and extension the guideline requirement for a combined duranic tencity/morphicity study in rate [23-   |

#### ToxRefDB



#### **CHRONIC/CANCER (CHR)**


Martin et al. (2008) Environ Hlth Persp doi:10.1289/ehp.0800074

#### MULTIGENERATION REPRODUCTIVE (MGR)

Martin et al. (2009) Toxicol Sci doi: 10.1093/toxsci/kfp080

#### PRENATAL DEVELOPMENTAL (DEV)

Knudsen et al. (2009) Reprod Toxicol doi: 10.1016/j.reprotox.2009.03.016





## **ToxRefDB in Predictive Modeling**

### STRENGTHS


- Source data from >2,000 guideline studies
- Puts >\$2B worth of legacy data into a computable form
- in vivo database anchoring HTS in vitro assays
- Enables comparison of endpoint incidence between species
- Searchable database will be public (<u>www.epa.gov/ncct/toxrefdb/</u>)


### LIMITATIONS

- Endpoints aggregated as independent features
- Data largely qualitative (LELs, LOAELS)
- Not all ToxCast<sup>™</sup> chemicals represented in ToxRefDB
- Not all ToxRefDB chemicals represented in ToxCast<sup>™</sup>
- Species dimorphism may link to biology or study design
- Limited mode of action information available in source DERs
- Not all endpoints routinely measured/captured




### Rat Liver Histopathology from Chronic Bioassays







### **Rat Liver Tumor Correlations**




|  | AR | PPARA | PPARG | HMGCS2 | CCL2 |
|--|----|-------|-------|--------|------|
| Malathion  |    |       |       |        |      |
| Mevinphos  |    |       |       |        |      |
| Ametryn  |    |       |       |        |      |
| Simazine   |    |       |       |        |      |
| Acetochlor                                       |    |       |       |        |      |
| Dimethenamid                                     |    |       |       |        |      |
| Vinclozolin                                      |    |       |       |        |      |
| Cyclanilide                                      |    |       |       |        |      |
| Dichlobenil                                      |    |       |       |        |      |
| Fludioxonil                                      |    |       |       |        |      |
| Imazalil   |    |       |       |        |      |
| 2,5-Pyridinedicarboxylic acid,<br>dipropyl ester |    |       |       |        |      |
| Pymetrozine                                      |    |       |       |        |      |
| Tebufenpyrad                                     |    |       |       |        |      |
| Isoxaflutole                                     |    |       |       |        |      |
| Lactofen   |    |       |       |        |      |
| Diclofop-methyl                                  |    |       |       |        |      |
| Oxadiazon  |    |       |       |        |      |
| Diethylhexyl phthalate                           |    |       |       |        |      |
| Carbaryl   |    |       |       |        |      |
| Tepraloxydim                                     |    |       |       |        |      |
|  |    |       |       |        |      |

Office of Research and Development National Center for Computational Toxicology

Fisher's Exact test, p<0.01



### Gene Networks Associated with Progression of Rat Liver Tumor Endpoints





## Some Challenges Faced or to be Faced


- Quality control of the chemical library
  - Acceptable purity, stability, and organization
- Defining/normalizing conc. response ranges
- Definition/Calculation of a hit
  - Minimum fold change; minimum r-squared; limit on Hill function
- Interpretation of hits and causality
  - Statistical vs. biological relevance
  - Association vs. causation
- Assay performance
  - Replicates, artifacts
- Sufficient coverage of biological pathways
  - Including those that represent tissue level processes
- Incorporation of metabolic competency
- Establishment of target prediction
  - Pathway perturbation
  - Rodent bioassay data
  - Rodent mechanistic studies
  - Human effects
- Sufficient representation of positives to predict against



### Potential Application to Chemical Programs: Endocrine Profiling & Prioritization


#### EDSP (Currently 67)

- 53 in ToxCast\_320
- Tiered testing program
- Regulatory capacity to request data under FFDCA
- -Mandate to test all chemicals
- Current practice:
  - Exposure based chemical selection
  - Not selected based on potential endocrine disruption
  - Two-tier system
- Potential need:
  - Pre-screen for ER, AR, or TR activity
  - Priority setting/targeted testing once expanded to evaluating all chemicals



Each chemical signature/ gives a priority score (ToxScore) that can be ranked along any domain

ToxScore = f(In vitro assays + Chemical properties + Pathways + In vivo endpoints)



### **ToxCast Hazard-Based Prioritization**

ToxScore = f(Chemical properties + In vitro assays + Pathways + Dosimetry)(II) Systemic Cancer (I) **Chemical properties** (e.g. benzene fragment) In vitro assays (e.g. p53 activation) **Pathways** (e.g. DNA damage repair) **Dosimetry** (e.g. biotransformation) Features for each toxicity sector are selected for specific prioritizations; different chemical properties, assays, pathways and dosimetry for specific types of toxicity testing. (III) Reproductive **Developmental (IV)**  $\mathsf{ToxScore} = \sum_{i=1}^{C} \mathsf{w}_{c} * \mathsf{chemProp}_{c} + \sum_{i=1}^{I} \mathsf{w}_{i} * \mathsf{assay}_{i} + \sum_{i=1}^{P} \mathsf{w}_{p} * \mathsf{pathway}_{p} + \sum_{i=1}^{L} \mathsf{w}_{e} * \mathsf{dosimetry}_{e}$ Chemical<sub>B</sub> Chemical<sub>C</sub> Chemical<sub>A</sub> Chemical<sub>D</sub> **Example ToxScores** prioritizing chemicals for Cancer, Systemic, Reproductive or Developmental testing, respectively. **(I) (III) (II)** Ίν

Reif and Dix, Unpublished

## **Prioritization Product Timeline**

| Phase | Number of<br>Chemicals | Chemical Criteria                       | Purpose                          | Number of<br>Assays | Cost per<br>Chemical | Target<br>Date |
|-------|------------------------|---|----------------------------------|---------------------|----------------------|----------------|
| la    | 320                    | Data Rich<br>(pesticides)               | Signature<br>Development         | 552                 | \$20k                | FY07-09        |
| lb    | 15                     | Nanomaterials                           | Pilot                            | 166                 | \$10K                | FY09           |
| lla   | >300                   | Data Rich Chemicals                     | Validation                       | >400                | ~\$20 -25k           | FY09-11        |
| llb   | >100                   | Known Human<br>Toxicants                | Extrapolation                    | >400                | ~\$20 -25k           | FY09-11        |
| lic   | >300                   | Expanded Structure<br>and Use Diversity | Extension                        | >400                | ~\$20 -25k           | FY09-11        |
| lld   | >12                    | Nanomaterials                           | PMN                              | >200                | ~\$15-20K            | FY10-11        |
| 111   | Thousands              | Data poor                               | Prediction and<br>Prioritization | >300                | ~\$15-20k            | FY11-12        |
| FY07  | FY08                   | 8 FY09                                  | FY1                              | .0                  | FY11                 | FY12           |

Proof of Concept: ToxCast

Verification/Extension

Reduce to Practice

Tox21



## Phase II Plans

- Done in conjunction with Tox21 10k Library
  - -Subset of 700 will seed Phase II

### Chemical Diversity

- -More food use active pesticides (~100-200)
- -Pesticidal antimicrobials & inerts (~100-200)
- -Failed pharmaceuticals (preclinical and clinical, ~100-150)
- -"Green" chemicals
- -HPV Categories
- -Liver toxicants
- -OECD Molecular Screening Group nominations
- Evaluation of Phase I Assays
- Additional assays via competitive procurements, collaborative partners...